(1S)-1-C-(4-Aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-1,4-anhydro-2-azido-2-deoxy-2-C-methyl-D-ribitol | 1596350-45-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S)-1-C-(4-Aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-1,4-anhydro-2-azido-2-deoxy-2-C-methyl-D-ribitol
• 英文别名: (2R,3S,4R,5S)-5-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-4-azido-2-(hydroxymethyl)-4-methyloxolan-3-ol
• CAS: 1596350-45-6
• 化学式: C11H14N8O3
• 分子量: 306.28
• InChiKey: VUDXAENROIEKRN-HGIWHZBTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] 2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS NUCLÉOSIDES SUBSTITUÉS 2'-DISUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014059902A1

  公开（公告）日：2014-04-24

  2'-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed:(1), wherein A is N3 or NH2 and X, Y, R1, R2, R3, R4,R5 and R18 are as defined herein. Compositions comprising at least one 2'-disubstituted nucleoside derivative, and methods of using the 2'-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed.

  本文披露了公式(I)的2'-二取代核苷衍生物及其药学上可接受的盐：(1)，其中A为N3或NH2，X、Y、R1、R2、R3、R4、R5和R18如本文所定义。本文还披露了包含至少一种2'-二取代核苷衍生物的组合物，以及使用这些2'-二取代核苷衍生物治疗或预防患者HCV感染的方法。
• 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160045526A1

  公开（公告）日：2016-02-18

  2′-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (1), wherein A is N 3 or NH 2 and X, Y, R 1 , R 2 , R 3 , R 4 , R 5 and R 18 are as defined herein. Compositions comprising at least one 2′-disubstituted nucleoside derivative, and methods of using the 2′-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed.
• US9457039B2
  申请人：——

  公开号：US9457039B2

  公开（公告）日：2016-10-04